The FDA approved the pill Nereus (tradipitant) as a new treatment for vomiting caused by motion sickness, with fewer side ...

Millions of Americans can now look forward to a better time traveling, with the US Food and Drug Administration (FDA) ...

Analysts raise price targets for Vanda Pharmaceuticals after FDA approved a motion sickness drug, citing growth potential.

Does motion sickness turn you into a green, spewing mess? For plenty of people, the answer is yes. Current remedies may or ...

Tradipitant is a selective human substance P/neurokinin-1 receptor antagonist approved for the prevention of vomiting induced by motion in adults.

FDA approval of Vanda’s Nereus marks a rare and meaningful regulatory milestone, introducing the first new pharmacologic ...

The scopolamine skin patch (Transderm Scōp), approved in 1979, was the last drug sanctioned by the FDA to prevent motion ...

Two Phase 3 real-world trials, conducted on boats, showed that NEREUS significantly reduced vomiting compared with placebo.

Jefferies analysts envision a steady launch curve that could ultimately drive meaningful sales from people who are ...

Vanda Pharmaceuticals has received FDA approval for Nereus (tradipitant), an oral NK-1 receptor antagonist developed to prevent motion-induced vomiting. The approval makes Nereus the first new ...

Vanda also sells sleep disorder drug Hetlioz, which reached the market in 2014, and relapsing multiple sclerosis treatment Ponvory, which was approved in 2021. The FDA is scheduled on Jan. 7 to decide ...